NCT02869321 2019-05-13
ANTALGIP
Central Hospital, Nancy, France
Phase 4 Completed
Clinical Trials
3 trialsNCT00842829 2012-10-01
Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 4 Terminated
NCT00576173 2010-04-28
An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients
Johnson & Johnson Taiwan Ltd
Phase 4 Completed